Package Includes Instrumentation and Application to Conform with Current U.S. FDA Methodology

WALTHAM, MA -- October 11, 2007 – PerkinElmer Life and Analytical Sciences, a global leader in application-focused measurement and analysis solutions, today announced a complete analyzer using gas chromatography/mass spectrometry (GC/MS) for the determination of melamine adulteration in protein-based foods. PerkinElmer’s Melamine Analyzer includes all instrumentation, consumables and applications resources needed to screen for melamine contamination. 

“With this system, laboratories can be confident that the analysis they are running is accurate and conforms with the most recent guideline from the U.S. Food and Drug Administration (FDA) for screening of wheat gluten, rice protein, corn gluten and soy protein,” said Eric Ziegler, Vice President of Chromatography for PerkinElmer Life and Analytical Sciences. “We were thrilled to put our deep expertise to work on a complete solution for the analysis of melamine adulteration.  It’s an example of the kind of application-focused solutions customers will be seeing more of from PerkinElmer to help enable scientists to improve and protect our world.”

The method for the Melamine Analyzer was developed in collaboration with Flora Research Laboratories, an FDA and DEA-registered independent testing laboratory specialized in natural products.  Ziegler noted that PerkinElmer is the first analytical solutions provider to offer a system to analyze melamine using GC/MS technology. 

Melamine is a nitrogen-rich industrial chemical that became well-known in North America recently after its presence in wheat gluten was linked with renal failure in dogs and cats*. The U.S. FDA quickly issued a standard test method for the analysis of melamine in protein materials using GC/MS.  The Melamine Analyzer includes a Clarus® 600 T GC/MS with autosampler and TurboMass™ GC/MS software, all consumables needed for analysis and an application CD for rapid ramp-up.  The application CD includes methods and sample data, a library of derivatized compounds spectra of melamine and related compounds, a melamine application guidebook and an application note that describes the analytical method in detail.

Due to the high financial and health risks posed by the presence of melamine, many data quality checks (QC) are necessary to confirm results.  In addition to high and low-level standards, the QC needed for this method includes a solvent blank, analysis of pyridine solvent and derivatization reagent, a method blank, un-spiked solvent carried through the extraction process and a matrix-spike sample at both the low and high levels. 

Although the U.S. FDA method is pass/fail, PerkinElmer’s Clarus 600 GC/MS provides the sensitivity to achieve a semi-quantitative result for added confidence. 

For more information, visit www.perkinelmer.com/melamine.

PerkinElmer instrumentation is used in food quality and food safety research and testing, encompassing authenticity, potency, manufacturing and contamination that directly impacts the health of all living things.  PerkinElmer can help test the safety of the food supply from the source of ingredients to the final product with a high level of sensitivity and reliability. 

Factors Affecting Future Performance
This press release contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities. Words such as “believes,” “intends,” “anticipates,” “plans,” “expects,” “projects,” “forecasts,” “will” and similar expressions, and references to guidance, are intended to identify forward-looking statements.  Such statements are based on management’s current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct.  A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements.  These factors include, without limitation: (1) our failure to introduce new products in a timely manner; (2) our ability to execute acquisitions and license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable; (3) our failure to protect adequately our intellectual property; (4) the loss of any of our licenses or licensed rights; (5) our ability to compete effectively; (6) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (7) our ability to produce an adequate quantity of products to meet our customers’ demands; (8) our failure to maintain compliance with applicable government regulations; (9) regulatory changes; (10) economic, political and other risks associated with foreign operations; (11) our ability to retain key personnel; (12) restrictions in our credit agreement; (13) our ability to realize the full value of our intangible assets; and (14) other factors which we describe under the caption “Risk Factors” in our most recent annual report on Form 10-K and in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

Other Information
Health Sciences end markets include genetic screening, environmental, service, biopharma, and medical imaging.  Photonics markets include sensors and specialty lighting.